For nearly two years, much of the life sciences industry operated in survival mode. Capital was tight, financing windows were limited, and leadership teams focused on preserving runway. Hiring slowed dramatically, and many organizations learned to operate with extremely lean teams. However, the environment is beginning to shift. Capital markets have loosened. Companies are raising money again. M&A activity is picking up. Public market…